Oncofusion

start / graph / reg-breakthrough-and-accelerated-approval

Explainerstrong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.Q8-impact

Breakthrough therapy and accelerated approval: the menin field took the fast review and declined the shortcut

also called BTD · breakthrough therapy designation · accelerated approval · subpart H · FDORA 2022 · RTOR

Breakthrough therapy designation buys a drug company close, frequent attention from FDA during development; accelerated approval lets a drug be sold on a lab measure that is only expected to predict benefit, with a follow-up trial owed afterwards. Both menin inhibitors for leukaemia took the fast review, but neither was approved on the accelerated pathway - they were approved outright, which is a better outcome than the field usually gets.

The same thing, for a scientist

Breakthrough therapy designation (FDCA 506(a), created by FDASIA 2012 section 902) requires a serious or life-threatening condition plus preliminary clinical evidence of substantial improvement over available therapy on a clinically significant endpoint; it buys intensive FDA engagement, senior organisational commitment and rolling review, and explicitly does not lower the evidentiary standard for approval. Accelerated approval (FDCA 506(c); 21 CFR part 314 subpart H) permits approval on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, conditioned on a confirmatory trial. Section 3210 of FDORA 2022 gave FDA four new levers: it may require the confirmatory study to be underway before approval, it has a streamlined withdrawal procedure, sponsors must report confirmatory trial status publicly, and an internal Accelerated Approval Council was created. Revumenib holds breakthrough therapy designation for relapsed or refractory KMT2A-rearranged acute leukaemia and was reviewed under priority review, fast track and Real-Time Oncology Review, but the approved label carries no accelerated approval statement and the approval letter imposes no efficacy confirmatory trial - it is a regular approval. Ziftomenib likewise received full approval. The sharp finding sits elsewhere in the same approval letter: FDA waived the paediatric study requirement for patients under 1 year old as impossible or highly impracticable.

Go deeper
Breakthrough therapy designation: what it changes and what it does not

Criteria (FDCA 506(a), created by FDASIA 2012 section 902) 1: the drug is intended to treat a serious or life-threatening condition, and preliminary clinical evidence indicates it may demonstrate substantial improvement on a clinically significant endpoint over available therapies. "Preliminary clinical evidence" means human data - so unlike orphan designation, BTD cannot be obtained on mechanism alone.

What it buys 1: all fast track features; intensive FDA guidance on efficient development starting as early as phase 1; organisational commitment involving senior FDA managers; a cross-disciplinary project lead; frequent meetings; eligibility for rolling review and priority review.

What it does not change: FDA is explicit that "regulatory standards to demonstrate safety and efficacy must still be met" 1. BTD is a process instrument. It compresses calendar time and improves the quality of sponsor-agency dialogue; it does not lower the bar.

Used here? Yes. FDA granted revumenib breakthrough therapy designation in December 2022 for adult and paediatric patients with relapsed or refractory KMT2A-rearranged (MLLr) acute leukaemia, following fast track designation in June 2021; the eventual NDA also received priority review and was handled under Real-Time Oncology Review 4. Ziftomenib's sponsors state it received breakthrough therapy, fast track and priority review as well.

Accelerated approval: the shortcut and the debt it creates

The pathway (FDCA 506(c); 21 CFR part 314 subpart H for drugs, part 601 subpart E for biologics) 2. FDA may approve a product for a serious condition that fills an unmet medical need on the basis of a surrogate endpoint - "a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit" - or an intermediate clinical endpoint. In oncology the classic surrogate is overall response rate, or CR+CRh in acute leukaemia.

The obligation. The sponsor owes a confirmatory trial to verify clinical benefit. The label must state that continued approval may be contingent on that verification.

What FDORA 2022 changed. Section 3210 of the Food and Drug Omnibus Reform Act of 2022 (enacted in the Consolidated Appropriations Act, 2023) amended FDCA 506(c) to give FDA four things it previously lacked 3:

  1. Authority to require the confirmatory study be underway before approval. The Secretary "may require, as appropriate, a study or studies to be underway prior to approval, or within a specified time period after the date of approval." This is the single most consequential change; a trial that has not enrolled its first patient at approval historically often never finished.
  2. A streamlined withdrawal procedure where the sponsor fails to conduct a required postapproval study with due diligence, or the study fails to verify benefit.
  3. Mandatory public reporting of confirmatory trial status.
  4. An Accelerated Approval Council inside FDA, with published annual activity reports.

Why the debt matters empirically. Of 129 cancer drug-indication pairs granted accelerated approval 2013-2023, among the 46 with more than five years of follow-up, 63% converted to regular approval, 22% were withdrawn and 15% were still pending after a median 6.3 years - and fewer than half (20 of 46, 43%) demonstrated clinical benefit in confirmatory trials 10. A separate cohort of 102 converted indications found a median 3.1 years to conversion, and confirmed that initiating the confirmatory trial before approval was associated with faster conversion 11 - which is precisely the behaviour FDORA now lets FDA compel.

Was accelerated approval used for KMT2A? No - and this is worth stating plainly

Secondary coverage of the revumenib approval sometimes describes it as accelerated. It was not. Three primary-source checks:

  1. The approved label. The full prescribing information for REVUFORJ (NDA 218944, approval 2024-11-15) was read in full. The indication reads, without qualification: "REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older." The strings "accelerated approval" and "continued approval" do not appear anywhere in the document 5. An accelerated approval label is required to carry that statement.
  2. The approval letter. FDA's approval letter for NDA 218944 contains no subpart H language. Its postmarketing requirements (4730-1 through 4730-6) are imposed under FDCA 505(o)(3) and are about safety and pharmacokinetics - sudden death, QTc prolongation, differentiation syndrome, transaminase elevation, parathyroid hormone, hepatic and renal impairment dosing, OATP1B1 interaction. There is no efficacy confirmatory trial requirement 6.
  3. The second indication. FDA's announcement of the 2025-10-24 NPM1-mutant approval records priority review and fast track and does not use the term accelerated approval 7. Ziftomenib (Komzifti, 2025-11-13) is likewise reported as a full approval 12.

So the menin-inhibitor field, as of 2026-09-18, has taken every acceleration of review on offer - fast track, breakthrough, priority review, Real-Time Oncology Review - while accepting conventional evidentiary standards at approval. Given the JAMA data above, that is a genuinely good outcome and the field should get credit for it. It also means the classic accelerated-approval failure mode - a paediatric confirmatory trial that never finishes - is not the live risk here. A different one is.

The live risk: infants were waived out, in writing

The Pediatric Research Equity Act (21 U.S.C. 355c) requires a paediatric assessment with every application for a new active ingredient, unless waived, deferred or inapplicable. FDA's approval letter for revumenib says this, verbatim 6:

"We are waiving the pediatric study requirement for patients less than 1 year of age because necessary studies are impossible or highly impracticable. This is because of the small number and geographical dispersion of pediatric patients in this age group."

Read that against the disease. KMT2A rearrangement is the defining lesion of infant acute lymphoblastic leukaemia; the under-1 population is not an edge case of the KMT2A indication, it is the population in which KMT2A-rearranged leukaemia is most characteristic and most lethal. The first approved drug for KMT2A-rearranged acute leukaemia carries a statutory paediatric study waiver for exactly that group, on feasibility grounds, and the approved label states that safety and efficacy under 1 year "have not been established."

To be fair to the programme, the registrational cohort was genuinely paediatric-inclusive by the standards of adult oncology: 104 patients, median age 37 years (range 1-79), 24% under 17, including 13 infants under 2 years, 41 children aged 2 to under 12 and 16 adolescents 9. That is not a token. The waiver bites below 1 year, not below 18.

The contrast with the NPM1 arm is where the age problem is real. Ziftomenib's pivotal KOMET-001 cohort (n=112) had a median age of 69 years, range 22-86, with 63% aged 65 or older and no patients under 18 8. Revumenib's NPM1 cohort was similarly older. A commonly repeated claim that "the approved menin trials had a median age of 66-69" is true of the NPM1 studies and false of the KMT2A study; this node records the correction because getting it backwards inverts the policy argument.

Facts and figures
jurisdictionUS
btd statuteFDCA 506(a) (21 U.S.C. 356(a)); FDASIA 2012 section 902
accelerated approval statuteFDCA 506(c); 21 CFR part 314 subpart H; 21 CFR part 601 subpart E
fdora 2022 section3210
fdora confirmatory trial may be required underway pre approvaltrue
fdora expedited withdrawaltrue
btd changes evidentiary standardfalse
revumenib btdtrue
revumenib btd date2022-12
revumenib fast track date2021-06
revumenib kmt2a approval date2024-11-15
revumenib kmt2a approval typeregular
revumenib npm1 approval date2025-10-24
revumenib npm1 approval typeregular
ziftomenib approval date2025-11-13
ziftomenib approval typeregular
accelerated approval used for kmt2afalse
prea waiver under 1 yeartrue
kmt2a pivotal median age years37
kmt2a pivotal PCT under 1724
ziftomenib pivotal median age years69
kmt2a pivotal crcrh PCT21.2
used for kmt2atrue
as of2026-09-18
programmes
[
  "breakthrough therapy designation",
  "accelerated approval",
  "fast track",
  "priority review",
  "Real-Time Oncology Review"
]
kmt2a pivotal age range years
[
  1,
  79
]
ziftomenib pivotal age range years
[
  22,
  86
]
How this could bite us back
  • The bluntest distortion in this file is not accelerated approval - it is the PREA waiver. FDA's own approval letter waives the paediatric study requirement for patients under 1 year old as 'impossible or highly impracticable' because of 'the small number and geographical dispersion' of those patients. KMT2A rearrangement is the defining lesion of infant leukaemia. The regulatory system granted the first KMT2A drug an exemption from studying the population the lesion most characterises, and gave as its reason the very rarity and dispersion that the orphan and paediatric incentive programmes exist to overcome. The incentives and the obligations are pointed in opposite directions.
  • Breakthrough therapy designation is granted on the strength of early data in a hard-to-treat population, but nothing ties the designation to that population persisting in the registrational programme. A sponsor can earn BTD on a paediatric-inclusive KMT2A signal and then expand into the far larger adult NPM1 market, where accrual is faster and the commercial return is an order of magnitude larger. Revumenib's second indication arrived eleven months after its first, in a cohort where roughly half the patients were over 65. The designation pulled the programme forward; the market decided where forward pointed.
  • Accelerated approval on CR+CRh would have been available here and was not taken - but the counterfactual is instructive. Approving on a 21.2% CR+CRh rate with a confirmatory trial owed later would have created exactly the standing risk the JAMA data document: fewer than half of accelerated oncology approvals with five years of follow-up ever demonstrated clinical benefit, and 21% of confirmatory trials had not even started at approval. In a disease where the paediatric cohort accrues at a handful of patients per year worldwide, a confirmatory trial that is not underway at approval is a trial that may never read out. The field avoided this. The pathway still permits it.
  • FDORA gave FDA the power to require a confirmatory trial be underway, but it is discretionary ('may require, as appropriate'). Discretion applied to a sponsor with a large adult indication and a small paediatric one predictably lands on the adult side, where accrual makes the requirement cheap to satisfy. The statute does not distinguish a confirmatory trial that is feasible from one that is not, and it is the infeasible ones that need compelling.
  • The expedited withdrawal procedure has a paediatric asymmetry nobody discusses. Withdrawing an accelerated approval removes access for everyone in the indication. In an adult indication with alternatives that is a defensible correction; in relapsed infant KMT2A-rearranged leukaemia, where the alternative is salvage chemotherapy and transplant, withdrawal is not a neutral act. The streamlined procedure increases the chance that a drug children depend on is removed on the strength of an adult-dominated confirmatory trial that failed for adult-specific reasons.
  • A widely repeated claim - that the approved menin trials had a median age of 66 to 69 - is true of the NPM1 studies and false of the KMT2A study, whose median age was 37 with 24% of patients under 17 and 13 infants enrolled. Repeating the wrong number makes the paediatric case look worse than it is and, worse, aims the criticism at the one trial that got the age distribution closest to right. Distorted incentives deserve accurate accounting too.
Still open
  1. Was the 2025-10-24 NPM1 supplement to NDA 218944 a regular approval? FDA's announcement does not say 'accelerated', but the sNDA approval letter was not retrievable at the expected Drugs@FDA path and the supplemental labelling was not read.
  2. Is the Komzifti label free of accelerated-approval language? This node relies on trade press for that, which is the weakest link in it.
  3. On what evidence did FDA conclude that studies in patients under 1 year of age are 'impossible or highly impracticable' for a disease whose paradigm population is infants, and what would change that determination - an international consortium trial design, a registry-based commitment, an extrapolation framework?
  4. Now that FDA may require confirmatory trials to be underway before accelerated approval, has any paediatric oncology accelerated approval actually been conditioned that way since 2023?
Every source behind this entry (12)
  1. E1established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database

    Breakthrough therapy designation, created by section 902 of FDASIA 2012, requires a serious or life-threatening condition and preliminary clinical evidence of substantial improvement on a clinically significant endpoint over available therapies; it confers intensive FDA guidance, senior organisational commitment and rolling review eligibility, and does not change the regulatory standards for demonstrating safety and efficacy.

    Frequently Asked Questions: Breakthrough Therapies · US Food and Drug Administration · FDA (FDASIA implementation) 2026
    What this evidence cannot show

    FDA explanatory page; the operative text is FDCA 506(a) (21 U.S.C. 356(a)).

    Evidence that argues against this (1)
    • A statute or a programme page states what the law PERMITS, not how the agency exercises the discretion the law gives it. Every operative term here — serious condition, substantial improvement, unmet need, plausible medical use — is applied case by case and the reasoning is not published, so the text bounds the outer edge of what could happen and predicts nothing about a particular application. "Preliminary clinical evidence of substantial improvement" is the term that decides outcomes and it has no quantitative definition. U.S. Food and Drug Administration 2026
  2. E2established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database

    FDA's accelerated approval programme allows earlier approval of drugs for serious conditions that fill an unmet medical need on the basis of a surrogate endpoint thought to predict clinical benefit but not itself a measure of clinical benefit, with sponsors still required to conduct studies confirming the anticipated clinical benefit.

    Accelerated Approval Program · US Food and Drug Administration · FDA 2026
    What this evidence cannot show

    Retrieved 2026-09-18; page marked content current as of 2026-08-25. The page did not itself cite 21 CFR part 314 subpart H or FDCA 506(c); those citations come from the statute and regulations directly.

    Evidence that argues against this (1)
    • A statute or a programme page states what the law PERMITS, not how the agency exercises the discretion the law gives it. Every operative term here — serious condition, substantial improvement, unmet need, plausible medical use — is applied case by case and the reasoning is not published, so the text bounds the outer edge of what could happen and predicts nothing about a particular application. The surrogate-endpoint criterion is also where accelerated approval has drawn its sharpest criticism: confirmatory trials are frequently delayed and withdrawal of a failed accelerated approval has historically been slow, so the programme's description of itself does not describe its record. U.S. Food and Drug Administration 2026
  3. E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.news

    Section 3210 of the Food and Drug Omnibus Reform Act of 2022 amended FDCA 506(c) so that the Secretary may require a confirmatory study to be underway prior to approval or within a specified time after approval, created a streamlined withdrawal process where a sponsor fails to conduct a required postapproval study with due diligence, mandated public reporting of confirmatory trial status, and established an accelerated approval council within FDA.

    FDORA Changes to the FDA Accelerated Approval Program · Cooley LLP · Cooley client insight 2023
    What this evidence cannot show

    Law-firm analysis of the statute rather than the statutory text itself. FDORA was enacted as Division FF, Title III of the Consolidated Appropriations Act, 2023. The requirement that sponsors submit confirmatory-trial progress reports not less often than every 180 days is described in this and parallel analyses but was not read from the statute here.

    Evidence that argues against this (1)
    • This is a law firm's client alert, which is secondary commentary on a statute. The primary record is the Food and Drug Omnibus Reform Act of 2022 itself (enacted as Division FF, Title III of the Consolidated Appropriations Act, 2023, Public Law 117-328) and the amended text at 21 U.S.C. 356(c). Where a client alert and the statute differ, the statute governs, and client alerts routinely compress conditional language into flat statements — here, that the Secretary MAY require a confirmatory study to be underway, which is permissive rather than mandatory. Cooley client insight 2023
  4. E4moderate confidence 3 of 5: One strong study, or several smaller consistent ones.news

    FDA granted revumenib breakthrough therapy designation in December 2022 for adult and paediatric patients with relapsed or refractory KMT2A-rearranged (MLLr) acute leukaemia, following fast track designation in June 2021.

    What this evidence cannot show

    Company press release. FDA does not publish a searchable list of breakthrough therapy designations, so this class of claim cannot generally be verified against an agency source; FDA's own approval announcement independently confirms priority review and fast track.

    Evidence that argues against this (1)
    • A company press release is a primary record of what the COMPANY said and a secondary record of what FDA did. Breakthrough therapy designation is not independently published by FDA at the time of grant, so a sponsor announcement is often the only available source — which is a real limitation rather than a reason to discount it. The claim is correctly worded as what was announced. PR Newswire 2022
  5. E5established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database

    The approved prescribing information for REVUFORJ (revumenib), NDA 218944, approved 2024-11-15, states the KMT2A indication without qualification and contains no accelerated-approval statement and no statement that continued approval is contingent on verification of clinical benefit.

    REVUFORJ (revumenib) tablets, for oral use - Full Prescribing Information · Syndax Pharmaceuticals, Inc. / US Food and Drug Administration · Drugs@FDA label NDA 218944 (218944s000lbl.pdf) 2024
    What this evidence cannot show

    Established by full-text extraction of the PDF and exhaustive string search for 'accelerated approval' and 'continued approval', which returned no matches. This is the original s000 label; later supplements were not checked, and the 2025 NPM1 supplement carries its own labelling.

    Evidence that argues against this (1)
    • Some secondary coverage and at least one automated summary of FDA's approval announcement describe the revumenib KMT2A approval as an accelerated approval. The label and approval letter contradict this: the approval letter for NDA 218944 (re-fetched 2026-09-20, HTTP 200, 239,096-byte PDF) imposes only safety and pharmacokinetic postmarketing requirements under FDCA 505(o)(3) and no confirmatory efficacy trial, which is the marker an accelerated approval would carry. SOURCING NOT FOUND for the first sentence: a web search on 2026-09-20 for secondary coverage of the 2024-11-15 KMT2A approval using the term 'accelerated approval' returned no such source, so the claim that secondary coverage says this is recorded here as unsourced rather than removed. The citation attached supports the second sentence only. US Food and Drug Administration et al. 2024
  6. E6established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database

    FDA's approval letter for NDA 218944 imposes postmarketing requirements 4730-1 through 4730-6 under FDCA 505(o)(3) that are all safety or pharmacokinetic in nature with no efficacy confirmatory trial, and states: 'We are waiving the pediatric study requirement for patients less than 1 year of age because necessary studies are impossible or highly impracticable. This is because of the small number and geographical dispersion of pediatric patients in this age group.'

    NDA 218944 Approval Letter, REVUFORJ (revumenib) tablets · US Food and Drug Administration, Center for Drug Evaluation and Research · Drugs@FDA (218944Orig1s000ltr.pdf) 2024
    What this evidence cannot show

    Quotation extracted from the PDF text layer; the wording was read directly and is reproduced verbatim. Postmarketing commitments (as distinct from requirements) were not enumerated here.

    Evidence that argues against this (1)
    • No efficacy confirmatory trial among the postmarketing requirements is a striking observation and its interpretation is not fixed: a full approval carries no confirmatory obligation by construction, so the absence may record that this was not an accelerated approval rather than a gap in oversight. The waiver language is the part worth reading closely. U.S. Food and Drug Administration 2026
  7. E7strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.database

    FDA's announcement of the 2025-10-24 approval of revumenib for relapsed or refractory NPM1-mutant AML in adult and paediatric patients 1 year and older records priority review and fast track designation and does not describe the approval as accelerated; the reported efficacy was a CR+CRh rate of 23.1% (95% CI 13.5-35.2).

    FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation · US Food and Drug Administration, Oncology Center of Excellence · FDA Resources Information Approved Drugs 2025
    What this evidence cannot show

    Absence of the term 'accelerated approval' on an FDA announcement page is strong but not conclusive; the supplement's own labelling was not read. Confirming from the sNDA approval letter would settle it, and that letter was not retrievable at the expected Drugs@FDA path.

    Evidence that argues against this (1)
    • An absence observed through a public search interface on one date bounds what that interface returns, not what exists. Regulatory documents are published on lags that differ by agency and by document type, a 404 can reflect a URL scheme change, and designations under several of these programmes are explicitly not publicly disclosable — so the absence is partly structural. A press announcement is also a summary written for a general audience and omits designations routinely; absence from it is weak evidence about the regulatory record. U.S. Food and Drug Administration 2026
  8. E8established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database

    FDA's Drug Trials Snapshot for KOMZIFTI (ziftomenib), approved 2025-11-13 for adults with relapsed or refractory NPM1-mutant AML, reports a trial population (KOMET-001, NCT04067336, n=112) with median age 69 years, range 22-86, 70 patients (63%) aged 65 or older, and no patients under 18.

    Drug Trials Snapshots: KOMZIFTI · US Food and Drug Administration · FDA Drug Trials Snapshots 2025
    NCT04067336
    What this evidence cannot show

    Drug Trials Snapshots report the demographics of the population studied for the approved indication, not the whole development programme.

    Evidence that argues against this (1)
    • A Drug Trials Snapshot reports the demographics of the population studied, which for KOMET-001 is adults with a median age of 69. It is therefore evidence about who was enrolled and not about who the drug works in, and the absence of paediatric patients is a design fact rather than a finding. U.S. National Library of Medicine 2026
  9. E9established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.trial_registry

    In the pivotal KMT2A-translocated cohort of SNDX-5613-0700 (AUGMENT-101, NCT04065399, n=104) the median age was 37 years (range 1-79) with 25 patients (24%) under 17; the paediatric-use section of the label records 13 infants under 2 years, 41 children aged 2 to under 12 and 16 adolescents, and states that safety and efficacy in patients under 1 year have not been established.

    REVUFORJ (revumenib) tablets - Full Prescribing Information, sections 8.4 and 14.1 (Table 10) · Syndax Pharmaceuticals, Inc. / US Food and Drug Administration · Drugs@FDA label NDA 218944 2024
    NCT04065399
    What this evidence cannot show

    Paediatric counts in section 8.4 refer to the broader safety population (135 patients with KMT2A-translocated disease across studies), not solely the 104-patient efficacy cohort, so the two sets of age figures are not directly additive.

    Evidence that argues against this (1)
    • A median age of 37 in a study open from one year is the right fact for the commercial-gravity argument and it needs its complement stated: 25 of 104 patients (24%) were under 17 and the label records 13 infants. The distribution is not adult-only; it is adult-weighted, and the two support different conclusions about what a paediatric programme would have to add. Journal of Clinical Oncology 2025
  10. E10established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper

    Of 129 cancer drug-indication pairs granted accelerated approval from 2013 to 2023, among 46 with more than five years of follow-up 63% converted to regular approval, 22% were withdrawn and 15% remained ongoing after a median 6.3 years; fewer than half (20 of 46, 43%) demonstrated clinical benefit in confirmatory trials.

    Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval · Liu ITT, Kesselheim AS, Cliff ERS · JAMA 331(17):1471-1479 2024
    PMID 38583175DOI
    What this evidence cannot show

    Cohort ends in 2023, so it largely predates the operational effect of the FDORA 2022 authorities. Retrieved via PubMed.

    Evidence that argues against this (1)
    • This is the finding that should temper the whole entry rather than sit in it as one item: among accelerated approvals with more than five years of follow-up, a minority demonstrated clinical benefit in confirmatory trials. A designation is a statement about regulatory pathway and unmet need, not about eventual benefit, and this beat repeatedly uses designations as evidence of promise. JAMA 2024
  11. E11established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper

    Among 102 cancer indications granted accelerated approval between 1992 and 2022 and converted to regular approval by August 2024, median time to conversion was 3.1 years (IQR 1.9-4.8), 21 confirmatory trials (21%) were initiated only after accelerated approval, and initiation of the confirmatory study before approval was associated with shorter time to conversion.

    Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA. · Tibau A, Hwang TJ, Romano A, Borrell M, Gich I, Molto C, Kesselheim AS · JAMA Network Open 8(3):e252026 2025
    PMID 40136298DOI
    What this evidence cannot show

    Conditions on conversion, so indications that were withdrawn or remain pending are excluded from the timing analysis, which biases the median downward. Retrieved via PubMed.

    Evidence that argues against this (1)
    • And conversion to regular approval takes years, during which the indication stands on surrogate endpoints. For a paediatric population the interval matters more than the endpoint: a child treated during the confirmatory window is treated on the surrogate, and the beat's regulatory optimism does not price that. JAMA Network Open 2025
  12. E12moderate confidence 3 of 5: One strong study, or several smaller consistent ones.news

    Ziftomenib (Komzifti) received full FDA approval on 13 November 2025 for adults with relapsed or refractory NPM1-mutant AML, rather than accelerated approval.

    FDA Approves Ziftomenib for NPM1-Positive AML · The ASCO Post · The ASCO Post 2025
    What this evidence cannot show

    Professional trade press, not the label or approval letter. The Komzifti label was not read for this node; the approval-type claim should be confirmed against NDA 220305 labelling before being relied on.

    Evidence that argues against this (1)
    • Trade press reporting an approval is one step removed from the FDA record, and this entry cites FDA directly elsewhere. The substantive point the trade report adds is that the approval was FULL rather than accelerated, which matters for this entry's argument and should be checked against the FDA approval letter rather than the report. The ASCO Post 2025
Connected to